GENFIT (GNFT) Stock Price, News & Analysis

Company Overview

Genfit is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies and diagnostics for serious metabolic and inflammatory liver diseases. Founded and headquartered in Lille, France, the company has concentrated its efforts on nonalcoholic steatohepatitis (NASH), an area of significant unmet medical need. By combining expertise in molecular biology, chemistry and medical imaging, Genfit aims to deliver products that can both treat disease and improve diagnosis and monitoring of liver conditions.

The company’s lead therapeutic candidate, elafibranor (GFT505), is a first-in-class, dual PPAR alpha/delta agonist designed to address the underlying metabolic and inflammatory processes that drive NASH. Elafibranor has completed multiple Phase II and Phase III clinical studies assessing its efficacy and safety in patients with NASH, including those at risk for progression to fibrosis and cirrhosis. Genfit continues to explore additional indications and combination strategies to broaden the potential applicability of its pipeline assets.

In parallel with its therapeutic programs, Genfit has developed proprietary diagnostic technologies to support the noninvasive assessment of liver health. Through a combination of imaging biomarkers and blood-based tests, the company seeks to provide physicians with tools for early detection, staging and monitoring of liver disease progression. Genfit’s diagnostics platform is designed to complement its drug development efforts and may be applied across diverse patient populations.

Genfit operates in Europe and the United States, collaborating with clinical sites, academic institutions and industry partners to advance its research. The company is led by an experienced management team with backgrounds in biotechnology, pharmaceutical development and medical research. Genfit continues to pursue regulatory interactions and strategic collaborations to bring its therapies and diagnostics to patients worldwide.

Key Stats

• Today's Range: $3.85 to $4.16
• 50-Day Range: $3.61 to $4.50
• 52-Week Range: $2.55 to $6.42
• Volume: 6,202 shs
• Average Volume: 8,376 shs
• Market Capitalization: $196 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

GENFIT Stock Analysis - MarketRank™

GENFIT scored higher than 34% of companies evaluated by MarketBeat, and ranked 628th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

GENFIT has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

GENFIT has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for GENFIT are expected to decrease in the coming year, from $0.95 to ($0.57) per share.

Price to Book Value per Share Ratio

GENFIT has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of GENFIT has been sold short.

Short Interest Ratio / Days to Cover

GENFIT has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in GENFIT has recently decreased by 5.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GENFIT does not currently pay a dividend.

Dividend Growth

GENFIT does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.07% of the float of GENFIT has been sold short.

Short Interest Ratio / Days to Cover

GENFIT has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in GENFIT has recently decreased by 5.59%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for GNFT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GENFIT insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.20% of the stock of GENFIT is held by insiders.

Percentage Held by Institutions

Only 2.24% of the stock of GENFIT is held by institutions.

GNFT Stock Analysis - Frequently Asked Questions

How have GNFT shares performed this year?

GENFIT's stock was trading at $3.71 on January 1st, 2025. Since then, GNFT shares have increased by 4.6% and is now trading at $3.88.

When did GENFIT IPO?

GENFIT (GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

How do I buy shares of GENFIT?

Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GENFIT own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GENFIT investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), NVIDIA (NVDA), Occidental Petroleum (OXY), Vaxart (VXRT), American Airlines Group (AAL) and Carnival (CCL).

Company Calendar

• Today: 9/05/2025
• Next Earnings (Estimated): 9/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNFT
• CIK: 1757064
• Web: www.genfit.com
• Phone: (332) 016-4000
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for GENFIT: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +129.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 1.23
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: $76.77 million
• Price / Sales: 2.55
• Cash Flow: $0.07 per share
• Price / Cash Flow: 56.47
• Book Value: $1.50 per share
• Price / Book: 2.61

Miscellaneous

• Outstanding Shares: 50,000,000
• Free Float: 47,903,000
• Market Cap: $196 million
• Optionable: Not Optionable
• Beta: 1.16